Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Downgrades Duck Creek Technologies to Hold

Needham analyst Mayank Tandon downgrades Duck Creek Technologies (NASDAQ:DCT) from Buy to Hold.
byBenzinga Newsdesk
January 9, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Needham analyst Mayank Tandon downgrades Duck Creek Technologies (NASDAQ:DCT) from Buy to Hold.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Immutep Announced New Patent Granteds in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination

By Charles Gross
November 9, 5:54 AM
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, is pleased to announce the grant of two new patents (numbers 7160345 and 10- 2441425) entitled "Combined Preparations for the Treatment of Cancer" by the Japanese Patent Office and South Korean Patent Office, respectively

IMMP